查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2060261

急性骨髓性白血病市場分析及預測（至2035年）：類型、產品類型、技術、應用、最終用戶、功能、治療方法、疾病階段

Acute Myeloid Leukemia Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Functionality, Mode, Stage
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球急性骨髓性白血病(AML) 市場預計將從 2025 年的 39 億美元成長到 2035 年的 65 億美元，年複合成長率 (CAGR) 為 5.1%。 AML 市場主要以化療、標靶治療和幹細胞移植為中心，其中化療約佔 45% 的市場。急性骨髓性白血病標靶治療（包括 FLT3 抑制劑和 IDH 抑制劑）約佔 35%，幹細胞移植約佔 20%。該市場集中度適中，少數幾家大型企業佔據主導地位，但專注於特定治療方法的中小型生物技術公司仍有很大的市場進入空間。從患者趨勢來看，精準醫療的進步正推動接受標靶治療的患者數量穩定成長。

急性骨髓性白血病(AML) 市場按治療方法分類，其中化療作為長期以來的主要治療方法，仍佔據市場主導地位。同時，在基因譜分析和個人化醫療方法的推動下，標靶治療正日益受到關注。隨著我們對 AML 分子生物學認知的不斷深入，新型標靶藥物的研發正在加速，這些藥物有望改變治療模式並改善患者預後。

市場區隔
類型 急性早幼粒細胞白血病、髓母細胞（未分化）、髓母細胞（分化）、髓單核細胞白血病、單核細胞白血病、紅血球白血病、巨核細胞白血病等。
產品 化療藥物、標靶治療藥物、免疫治療藥物及其他
科技 細胞遺傳學、分子診斷、流式細胞技術等。
目的 醫院檢查室、臨床研究機構、學術機構及其他
最終用戶 醫院、診所、研究機構及其他
功能 診斷、治療、監測及其他
給藥途徑 靜脈注射、口服、其他
疾病階段 新診斷、復發/難治性、其他

急性髓系白血病（AML）市場的終端用戶包括醫院、診所和研究機構，其中醫院佔據主導地位。醫院擁有強大的優勢，這得益於其集中的專業醫療人員和先進的治療設施。研究機構在推動AML的研發方面發揮著至關重要的作用，為新治療方法和診斷技術的發現做出了貢獻。醫院與研究機構之間的合作對於將科學進展轉化為臨床實踐並最終改善患者預後至關重要。

區域概覽

北美憑藉其高度發展的腫瘤治療基礎設施和對癌症治療創新的高度重視，在急性骨髓性白血病)市場佔據主導地位。該地區受益於標靶治療和精準醫療方法的早期應用，以及廣泛的臨床研究活動。高額的醫療支出、健全的報銷機制和廣泛的專科癌症中心覆蓋，使得急性骨髓性白血病的診斷和治療得以有效進行。此外，主要醫療機構的存在以及新治療方法的持續批准進一步鞏固了該地區的市場主導地位，而人口老化也促使人們對先進治療方案的需求持續成長。

亞太地區是急性骨髓性白血病)市場成長最快的地區，這主要得益於醫療基礎設施的改善以及人們對癌症診斷和治療意識的提高。醫院和診斷設施的快速擴張，以及先進治療手段的普及，正在加速中國和印度等國家的市場成長。政府對癌症治療的支持措施、對臨床研究投入的增加以及經濟有效的治療方案的普及，進一步推動了治療的普及。此外，患者數量的增加和早期診斷率的提高所帶來的強勁需求，正使該地區成為全球市場的主要成長中心。

主要趨勢和促進因素

急性骨髓性白血病發病率上升和人口老化：

急性骨髓性白血病發病率的不斷上升，尤其是在老年族群中，是推動市場成長的主要因素。這種疾病在老年人中更為常見，而全球預期壽命的延長也加劇了患者數量的成長。診斷能力的提高和公眾意識的增強也使得病例能夠更早、更頻繁地被發現。不斷擴大的患者群體推動了對有效治療方法的需求，促使製藥公司加強研發投入，加速了整體市場的成長。

標靶治療和精準醫療的進展：

標靶治療、免疫療法和精準醫療的興起為市場帶來了巨大的機會。基因標靶藥物、CAR-T細胞療法和分子診斷等創新技術正在透過提供更個人化和有效的解決方案，改變治療方法。對患者基因譜分析的日益重視，使得治療方法的選擇更加精準，治療效果也得以提升。此外，豐富的新型治療方法研發管線和正在進行的臨床試驗，也為未來的治療開闢了新的道路。這些進步為企業開闢了新的成長途徑，並協助其開發差異化治療方法，以滿足尚未被滿足的醫療需求。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 急性早幼粒細胞白血病
    • 髓母細胞（未分化型）
    • 髓母細胞（成熟）
    • 髓單核細胞
    • 單核細胞
    • 紅血球白血病
    • 巨核細胞
    • 其他
  • 市場規模及預測：依產品分類
    • 化療藥物
    • 標靶治療
    • 免疫療法藥物
    • 其他
  • 市場規模及預測：依技術分類
    • 細胞遺傳學
    • 分子診斷
    • 流式細胞技術
    • 其他
  • 市場規模及預測：依應用領域分類
    • 醫院檢查室
    • 臨床研究機構
    • 學術機構
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 臨床科
    • 研究機構
    • 其他
  • 市場規模及預測：依疾病階段分類
    • 新診斷
    • 復發/難治性
    • 其他
  • 市場規模及預測：依給藥途徑分類
    • 靜脈
    • 口服
    • 其他
  • 市場規模及預測：依功能分類
    • 診斷
    • 治療
    • 監測
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 大公司的策略

第8章：公司簡介

  • Roche
  • Novartis
  • Bristol Myers Squibb
  • Pfizer
  • AbbVie
  • Amgen
  • Johnson and Johnson
  • Astellas Pharma
  • Celgene
  • Daiichi Sankyo
  • Gilead Sciences
  • Sanofi
  • AstraZeneca
  • Takeda Pharmaceutical
  • Eli Lilly and Company
  • Merck and Co
  • Bayer
  • Biogen
  • Incyte
  • Jazz Pharmaceuticals

第9章 關於我們

簡介目錄
Product Code: GIS27000

The global Acute Myeloid Leukemia market is projected to grow from $3.9 billion in 2025 to $6.5 billion by 2035, at a compound annual growth rate (CAGR) of 5.1%. The Acute Myeloid Leukemia (AML) market is characterized by its focus on chemotherapy, targeted therapy, and stem cell transplantation, with chemotherapy holding approximately 45% of the market share. Targeted therapies, including FLT3 inhibitors and IDH inhibitors, account for about 35%, while stem cell transplantation represents around 20%. The market is moderately consolidated, with a few key players dominating, yet there is significant room for smaller biotech firms focusing on niche therapies. Volume insights indicate a steady increase in the number of patients undergoing targeted therapies due to advancements in precision medicine.

The Acute Myeloid Leukemia (AML) market is segmented by type, with chemotherapy dominating due to its longstanding role as the primary treatment modality. Targeted therapies are gaining traction, driven by advancements in genetic profiling and personalized medicine approaches. The increasing understanding of AML's molecular biology is propelling the development of novel targeted agents, which are expected to transform treatment paradigms and improve patient outcomes.

Market Segmentation
TypeAcute Promyelocytic Leukemia, Myeloblastic (without maturation), Myeloblastic (with maturation), Myelomonocytic, Monocytic, Erythroleukemia, Megakaryoblastic, Others
ProductChemotherapy Drugs, Targeted Therapy Drugs, Immunotherapy Drugs, Others
TechnologyCytogenetics, Molecular Diagnostics, Flow Cytometry, Others
ApplicationHospital Laboratories, Clinical Research Institutes, Academic Institutes, Others
End UserHospitals, Clinics, Research Laboratories, Others
FunctionalityDiagnosis, Treatment, Monitoring, Others
ModeIntravenous, Oral, Others
StageNewly Diagnosed, Relapsed/Refractory, Others

End users in the AML market include hospitals, clinics, and research institutes, with hospitals being the predominant segment. The concentration of specialized healthcare professionals and advanced treatment facilities in hospitals drives their dominance. Research institutes are pivotal in advancing AML research and development, contributing to the discovery of novel therapies and diagnostic techniques. The collaboration between hospitals and research institutions is crucial for translating scientific advancements into clinical practice, thereby enhancing patient outcomes.

Geographical Overview

North America dominates the acute myeloid leukemia market due to its highly advanced oncology care infrastructure and strong focus on innovation in cancer therapeutics. The region benefits from early adoption of targeted therapies, precision medicine approaches, and extensive clinical research activities. High healthcare spending, strong reimbursement systems, and widespread access to specialized cancer centers enable effective diagnosis and treatment of Acute Myeloid Leukemia. In addition, the presence of leading pharmaceutical companies and continuous regulatory approvals for novel therapies further strengthen market leadership, while a growing aging population contributes to sustained demand for advanced treatment options.

Asia Pacific is the fastest-growing region in the acute myeloid leukemia market, driven by improving healthcare infrastructure and increasing awareness of cancer diagnosis and treatment. Rapid expansion of hospitals, diagnostic facilities, and access to advanced therapies is accelerating market growth across countries such as China and India. Government initiatives supporting cancer care, rising investments in clinical research, and increasing availability of cost-effective treatment options are further boosting adoption. Additionally, the growing patient population and improving early diagnosis rates are creating strong demand, positioning the region as a key growth hub in the global market.

Key Trends and Drivers

Rising Incidence of Acute Myeloid Leukemia and Aging Population:

The increasing incidence of Acute Myeloid Leukemia, particularly among the aging population, is a major driver for the market. The disease is more common in older adults, and the global rise in life expectancy is contributing to a growing patient pool. Improved diagnostic capabilities and increased awareness are also leading to earlier and more frequent detection of cases. This expanding patient base is driving demand for effective treatment options, encouraging pharmaceutical companies to invest heavily in research and clinical development, thereby accelerating overall market growth.

Advancements in Targeted Therapies and Precision Medicine:

The shift toward targeted therapies, immunotherapies, and precision medicine presents significant opportunities in the market. Innovations such as gene-targeted drugs, CAR-T cell therapies, and molecular diagnostics are transforming treatment approaches by offering more personalized and effective solutions. Increasing focus on genetic profiling of patients enables better treatment selection and improved outcomes. Additionally, a strong pipeline of novel therapies and ongoing clinical trials are expanding future treatment possibilities. These advancements are creating new growth avenues and enabling companies to develop differentiated therapies that address unmet clinical needs.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Stage
  • 2.7 Key Market Highlights by Mode
  • 2.8 Key Market Highlights by Functionality

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Acute Promyelocytic Leukemia
    • 4.1.2 Myeloblastic (without maturation)
    • 4.1.3 Myeloblastic (with maturation)
    • 4.1.4 Myelomonocytic
    • 4.1.5 Monocytic
    • 4.1.6 Erythroleukemia
    • 4.1.7 Megakaryoblastic
    • 4.1.8 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Chemotherapy Drugs
    • 4.2.2 Targeted Therapy Drugs
    • 4.2.3 Immunotherapy Drugs
    • 4.2.4 Others
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Cytogenetics
    • 4.3.2 Molecular Diagnostics
    • 4.3.3 Flow Cytometry
    • 4.3.4 Others
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Hospital Laboratories
    • 4.4.2 Clinical Research Institutes
    • 4.4.3 Academic Institutes
    • 4.4.4 Others
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Clinics
    • 4.5.3 Research Laboratories
    • 4.5.4 Others
  • 4.6 Market Size & Forecast by Stage (2020-2035)
    • 4.6.1 Newly Diagnosed
    • 4.6.2 Relapsed/Refractory
    • 4.6.3 Others
  • 4.7 Market Size & Forecast by Mode (2020-2035)
    • 4.7.1 Intravenous
    • 4.7.2 Oral
    • 4.7.3 Others
  • 4.8 Market Size & Forecast by Functionality (2020-2035)
    • 4.8.1 Diagnosis
    • 4.8.2 Treatment
    • 4.8.3 Monitoring
    • 4.8.4 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Stage
      • 5.2.1.7 Mode
      • 5.2.1.8 Functionality
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Stage
      • 5.2.2.7 Mode
      • 5.2.2.8 Functionality
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Stage
      • 5.2.3.7 Mode
      • 5.2.3.8 Functionality
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Stage
      • 5.3.1.7 Mode
      • 5.3.1.8 Functionality
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Stage
      • 5.3.2.7 Mode
      • 5.3.2.8 Functionality
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Stage
      • 5.3.3.7 Mode
      • 5.3.3.8 Functionality
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Stage
      • 5.4.1.7 Mode
      • 5.4.1.8 Functionality
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Stage
      • 5.4.2.7 Mode
      • 5.4.2.8 Functionality
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Stage
      • 5.4.3.7 Mode
      • 5.4.3.8 Functionality
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Stage
      • 5.4.4.7 Mode
      • 5.4.4.8 Functionality
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Stage
      • 5.4.5.7 Mode
      • 5.4.5.8 Functionality
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Stage
      • 5.4.6.7 Mode
      • 5.4.6.8 Functionality
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Stage
      • 5.4.7.7 Mode
      • 5.4.7.8 Functionality
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Stage
      • 5.5.1.7 Mode
      • 5.5.1.8 Functionality
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Stage
      • 5.5.2.7 Mode
      • 5.5.2.8 Functionality
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Stage
      • 5.5.3.7 Mode
      • 5.5.3.8 Functionality
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Stage
      • 5.5.4.7 Mode
      • 5.5.4.8 Functionality
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Stage
      • 5.5.5.7 Mode
      • 5.5.5.8 Functionality
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Stage
      • 5.5.6.7 Mode
      • 5.5.6.8 Functionality
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Stage
      • 5.6.1.7 Mode
      • 5.6.1.8 Functionality
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Stage
      • 5.6.2.7 Mode
      • 5.6.2.8 Functionality
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Stage
      • 5.6.3.7 Mode
      • 5.6.3.8 Functionality
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Stage
      • 5.6.4.7 Mode
      • 5.6.4.8 Functionality
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Stage
      • 5.6.5.7 Mode
      • 5.6.5.8 Functionality

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Roche
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Novartis
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Bristol Myers Squibb
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Pfizer
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 AbbVie
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Amgen
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Johnson and Johnson
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Astellas Pharma
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Celgene
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Daiichi Sankyo
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Gilead Sciences
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Sanofi
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 AstraZeneca
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Takeda Pharmaceutical
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Eli Lilly and Company
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Merck and Co
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Bayer
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Biogen
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Incyte
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Jazz Pharmaceuticals
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us